InvestorsHub Logo
Followers 3
Posts 54
Boards Moderated 0
Alias Born 01/22/2014

Re: None

Wednesday, 03/12/2014 4:59:33 PM

Wednesday, March 12, 2014 4:59:33 PM

Post# of 408874
excellent post rollin2nyte..

Precisely why Elite shall greatly benefit from the opioid treatment market...

Over at Bloomberg, writer Drew Armstrong notes that FDA pain drug czar Bob Rappaport has already said the agency would consider jerking Zohydro from the market if an abuse-resistant version become available..."



For those who keeping dwelling on the identity of the consulting firm...

Review the DD presented on this board, PR's etc. to date, consider why you invested your money in ELTP in the first place and evaluate ELTP's current value based on the successful trials and growing patent estate we have been presented with to date.

Then considering the growing pressure placed on the FDA to remove from the market any opioid product that does not contain ADT/ART formulation, follow that up with the future successful marketing of this line of drugs in the US, (add: Canada and Europe) and then see where you place the value of the company...

Imo, you'll soon understand the name of the firm is surely not that important when you, the average joe or jane investor can easily come up with a similar (or higher) valuation of Elite Pharmaceuticals (ELTP) and probably already did prior to arriving at your decision to invest in ELTP.

All the Best -- greater times ahead


GLTA

Enigma

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent ELTP News